The burgeoning popularity of retatrutide, initially for diabetes , is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Access these medications remains a complex landscape, with public healthcare system provision currently limited and private clinics offering therapy at a premium . Worries are